The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Elissa J. Schwartz net worth and biography

Elissa Schwartz Biography and Net Worth

Director of Galectin Therapeutics

Elissa J. Schwartz, Ph.D. is a disease modeler with extensive experience in clinical research, biomathematics and biostatistics. She is currently a professor of biological sciences and mathematics at Washington State University (WSU). She received a PhD in Biomedical Sciences from Mount Sinai–NYU, a BA in Mathematics from UC Berkeley, and interdisciplinary postdoctoral training in Biomathematics and Biostatistics from UCLA. She is also affiliated with the WSU College of Veterinary Medicine in microbiology and pathology, and she is currently on the WSU COVID-19 modeling task force. Dr. Schwartz is the author of over 30 scientific publications on infectious disease, immune response, and biological modeling. She serves on the Board of Directors for the Society for Mathematical Biology, and she previously served as a consultant for Pharmerit International, LP, a pharmaceutical economics company. Dr. Schwartz has held fellowships with the Mathematical Biosciences Institute (Ohio State University) and the African Institute for Mathematical Sciences (Cape Town, South Africa), and she served on the teaching faculty for courses in British Columbia, India, and Nepal.

How do I contact Elissa J. Schwartz?: The corporate mailing address for Dr. Schwartz and other Galectin Therapeutics executives is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. Galectin Therapeutics can also be reached via phone at (678) 620-3186 and via email at [email protected]. Learn More on Elissa J. Schwartz's contact information.
Has Elissa J. Schwartz been buying or selling shares of Galectin Therapeutics?: Elissa J. Schwartz has not been actively trading shares of Galectin Therapeutics during the past quarter. Most recently, on Friday, January 21st, Elissa J. Schwartz bought 1,000 shares of Galectin Therapeutics stock. The stock was acquired at an average cost of $2.00 per share, with a total value of $2,000.00. Learn More on Elissa J. Schwartz's trading history.
Who are Galectin Therapeutics' active insiders?: Galectin Therapeutics' insider roster includes Kevin Freeman (Director), Elissa Schwartz (Director), and Richard Zordani, Jr. (Director). Learn More on Galectin Therapeutics' active insiders.
Are insiders buying or selling shares of Galectin Therapeutics?: During the last twelve months, Galectin Therapeutics insiders bought shares 7 times. They purchased a total of 12,259 shares worth more than $34,100.70. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 21,323 shares worth more than $65,248.38. The most recent insider tranaction occured on October, 23rd when Director Kary Eldred bought 500 shares worth more than $1,300.00. Insiders at Galectin Therapeutics own 52.7% of the company. Learn More about insider trades at Galectin Therapeutics.
Information on this page was last updated on 10/23/2024.

Elissa J. Schwartz Insider Trading History at Galectin Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/21/2022	Buy	1,000	$2.00	$2,000.00

Elissa J. Schwartz Buying and Selling Activity at Galectin Therapeutics

Galectin Therapeutics Company Overview

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Today's Range

Now: $2.84

$2.76

$2.90

50 Day Range

MA: $2.69

$2.47

$3.00

2 Week Range

Now: $2.84

$1.55

$4.27

Volume

53,640 shs

Average Volume

145,387 shs

Market Capitalization

$178.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Financial Prophecy

From Porter & Company | Ad